Publications

Export 6 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Abdelhalim, H., M. Khairy, A. Amir, and M. Essam, "Assessment of protective serum anti-HBsab levels among previously HBV vaccinated medical residents and its relation to duration and doses of vaccine – single center study", CONFERENCE ON LIVER DISEASE IN AFRICA 2020(COLDA), South Africa, 11 September, 2020.
Anwar, I., M. Said, M. Essam, K. Hosny, D. Mansour, N. Zayed, A. E. adway, M. Elamir, S. mogawr, M. Shazly, et al., "Outcome of Corona Virus Disease (COVID-19) in Egyptian Cohort of Long-Term Liver Transplant Recipients: Single Center Experience", Journal of Transplant Surgery, 2021. outcome_of_corona_virus_disease_covid-19_in_egypti.pdf
E
El-Bendary, M., S. Abd-Elsalam, T. Elbaz, W. El-Akel, A. Cordie, T. Elhadidy, H. Elalfy, K. Farid, M. Elegezy, A. El-Badrawy, et al., "Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.", Expert review of anti-infective therapy, pp. 1-5, 2021. Abstract

BACKGROUND: Limited experimental and clinical evidence suggests a potential role for sofosbuvir/daclatasvir in treating COVID19. We aim to evaluate the efficacy of generic sofosbuvir/daclatasvir in treating COVID-19 patients with pneumonia.

RESEARCH DESIGN AND METHODS: This multicenter prospective study involved 174 patients with COVID-19. Patients were randomized into two groups. Group A (96 patients) received sofosbuvir (400 mg)/daclatasvir (60 mg) for 14 days in combination with conventional therapy. Group B (78 patients) received conventional therapy alone. Clinical, laboratory, and radiological data were collected at baseline, after 7, 14, and 28 days of therapy. Primary endpoint was rate of clinical/virological cure.

RESULTS: A lower mortality rate was observed in group (A) (14% vs 21%, P = 0.07). After 1 month of therapy, no differences were found in rates of ICU admission, oxygen therapy, or ventilation. Additionally, a statistically significant shorter duration of hospital stay (9% vs 12%, P < 0.01) and a faster achievement of PCR negativity at day 14 (84% versus 47%, P < 0.01) were noticed in group (A).

CONCLUSION: Adding sofosbuvir/daclatasvir to conventional therapy of COVID-19 is promising. Their use is associated with shorter hospital stay, faster PCR negativity and may be reduced mortality.

K
Khorshid, M., N. Bakheet, S. Abdallah, M. Essam, and A. Cordie, "COVID-19: A strong call for remote medicine in inflammatory bowel disease.", Journal of digestive diseases, vol. 21, issue 10, pp. 597-599, 2020.
M
Mogawer, M. - S., A. Abdel-Maqsod, M. El-Shazly, A. Salah, O. Abdelaziz, A. Abdel-Ghani, M. Essam, and A. A. Abdellatif, Tacrolimus-induced posterior reversible encephalopathy syndrome presenting as left upper limb monoplegia, convulsions, and sudden blindness: case report, , 2020. s43066-020-00064-6.pdf
N
Negm, M., A. Bahaa, A. Farrag, R. M. Lithy, H. A. Badary, M. Essam, S. Kamel, M. Sakr, W. Abd El Aaty, M. Shamkh, et al., "Effect of Ramadan intermittent fasting on inflammatory markers, disease severity, depression, and quality of life in patients with inflammatory bowel diseases: A prospective cohort study.", BMC gastroenterology, vol. 22, issue 1, pp. 203, 2022. Abstract

BACKGROUND: Intermittent fasting (IF) during the month of Ramadan is part of the religious rituals of Muslims. The effect of intermittent fasting on disease activity in inflammatory bowel diseases (IBD) is still unknown. This is the first study to assess the effect of IF during Ramadan on inflammatory markers in patients diagnosed with IBD. The effects on clinical disease activity, quality of life, and levels of depression were also assessed.

METHODS: Patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) who intended to observe Ramadan fasting were recruited. The following were assessed immediately before and at the end of Ramadan: Serum CRP and stool calprotectin, partial Mayo score, Harvey Bradshaw index (HBI), Simple IBD questionnaire (SIBDQ), and Hamilton depression scale questionnaire.

RESULTS: 80 patients diagnosed with IBD were recruited (60 UC, 20 CD). Serum CRP and stool calprotectin did not show a significant change before vs after fasting (median CRP 0.53 vs 0.50, P value = 0.27, Calprotectin 163 vs 218 respectively, P value = 0.62). The partial Mayo score showed a significant rise after fasting (median 1 before vs 1 after fasting, mean: 1.79 vs 2.33 respectively, P value = 0.02). Harvey-Bradshaw index did not show a significant change after fasting (median 4 vs 5, P value = 0.4). Multiple linear regression revealed that older age and a higher baseline calprotectin were associated with a higher change in Mayo score after fasting (P value = 0.02 and P value = 0.01, respectively). No significant change was detected in SIBDQ or Hamilton depression scale scores.

CONCLUSIONS: In patients diagnosed with UC, IF during Ramadan was associated with worsening of clinical parameters, the effect was more pronounced in older patients and those with higher baseline calprotectin levels. However, IF during Ramadan was not associated with an adverse effect on objective inflammatory markers (CRP and calprotectin).

Tourism